Track topics on Twitter Track topics that are important to you
Focal HDR Brachytherapy Boost To Stereotactic Radiotherapy PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Focal HDR Brachytherapy Boost To Stereotactic Radiotherapy articles that have been published worldwide.
We have published hundreds of Focal HDR Brachytherapy Boost To Stereotactic Radiotherapy news stories on BioPortfolio along with dozens of Focal HDR Brachytherapy Boost To Stereotactic Radiotherapy Clinical Trials and PubMed Articles about Focal HDR Brachytherapy Boost To Stereotactic Radiotherapy for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Focal HDR Brachytherapy Boost To Stereotactic Radiotherapy Companies in our database. You can also find out about relevant Focal HDR Brachytherapy Boost To Stereotactic Radiotherapy Drugs and Medications on this site too.
Assess the feasibility, safety and efficacy of Stereotactic ablative radiotherapy (SAbR) as alternative for intracavitary (ICBT) /interstitial brachytherapy (IBT) boost for locally advanced cervical cancer (LACC) after initial chemoradiation METHODS: A single arm institutional phase II study of SAbR as boost for LACC was conducted .Eligible patients had LACC FIGO 2009 stage IB2-IVB, performance status(PS) 0-3, and one of the following : medically unfit or refused ICBT or tumor extent required IBT for covera...
To demonstrate feasibility and toxicity of linear accelerator-based stereotactic radiation therapy boost (SBRT) for prostate cancer, mimicking a high-dose-rate brachytherapy boost.
The purpose of this article was to report the treatment effect of image-guided high-dose-rate interstitial brachytherapy boost in the radical radiotherapy for a huge metastatic carcinoma of cervical lymph nodes from an unknown primary site. The patient was a 75-year-old male. A diagnostic biopsy showed metastatic squamous cell carcinoma and the tumour size was 7.5×6.5×11.5cm before treatment (N3; AJCC 7th). After external beam radiotherapy with a dose of 60Gy in 30 fractions, the residual tumour (6.2×4.7...
Stereotactic body radiotherapy (SBRT) for prostate cancer (PCa) is gaining interest by the recent publication of the first phase III trials on prostate SBRT and the promising results of many other phase II trials. Before long term results became available, the major concern for implementing SBRT in PCa in daily clinical practice was the potential risk of late genitourinary (GU) and gastrointestinal (GI) toxicity. A number of recently published trials, including late outcome and toxicity data, contributed to...
Advanced forms of prostate cancer (PCa) radiotherapy with either external beam therapy or brachytherapy delivery techniques aim for a focal boost and thus require accurate lesion localization and lesion segmentation for subsequent treatment planning. This study prospectively evaluated dynamic contrast-enhanced computed tomography (DCE-CT) for the detection of prostate cancer lesions in the peripheral zone (PZ) using qualitative and quantitative image analysis compared to multiparametric magnet resonance ima...
This survey aimed to document the current practice patterns of postoperative radiotherapy (RT), including vaginal vault brachytherapy (VVB) and external beam radiotherapy (EBRT), in the management of patients with endometrial cancer.
Radiotherapy (RT) is a cornerstone in the management of advanced stage III and stage IV non-small-cell lung cancer (NSCLC) patients. Despite international guidelines, clinical practice remains heterogeneous. Additionally, the advent of stereotactic ablative RT (SABR) and new systemic treatments such as immunotherapy have shaken up dogmas in the approach of these patients. This review will focus on palliative thoracic RT for NSCLC but will also discuss the role of stereotactic radiotherapy, endobronchial bra...
Stereotactic body radiotherapy has emerged as an attractive alternative to conventional radiotherapy for spinal metastases. However, it has limitations, including the need for advanced techniques and specific adverse effects. The present trial aimed to validate the feasibility and safety of stereotactic body radiotherapy in Japanese patients with spinal metastases.
in the setting of metastatic malignancies, the role of concurrent stereotactic radiosurgery (SRS)/stereotactic radiotherapy (SRT) and immune-checkpoint inhibitors (ICI) is increasing. Few data are available about effectiveness and safety of this strategy.
and purpose: To assess the efficacy and safety of salvage stereotactic body radiotherapy (SBRT) in patients with biopsy-proven local prostate cancer recurrence after radiotherapy.
The aim of this analysis was to assess the 5-year tolerance and survival in patients undergoing hypofractionated stereotactic boost after external beam radiotherapy (EBRT) for intermediate-risk prostate cancer.
Palliative antalgic treatments represent an issue for clinical management and a challenge for scientific research. Radiotherapy (RT) plays a central role. Techniques such as stereotactic body radiotherapy (SBRT) were largely investigated in several phase 2 studies with good symptom response, becoming widely adopted. However, evidence from randomized, direct comparison of RT and SBRT is still lacking.
The standard treatment for patients with early-stage prostate cancer are operation and radiotherapy. Stereotactic body radiation therapy (SBRT) is one of the new radiotherapy methods. The aim of the study was to analyze tumor control of prostate cancer patients treated with SBRT.
Spine stereotactic body radiotherapy (sSBRT) is commonly limited to 1 or 2 vertebral levels given a paucity of efficacy and toxicity data when more than 2 levels are treated.
Intraoperative radiotherapy (IORT) with a 50-kV x-ray is used for a tumor bed boost during breast-conserving surgery. This study evaluated the anatomicosurgical factors associated with cancellation of planned IORT.
Stereotactic body radiotherapy (SBRT) is an effective treatment for spinal metastases in the vertebral body. There is variation between practitioners about appropriate target delineation. As such, we compare tumor control, rates of compression fracture, and pain control for patients treated with stereotactic body radiotherapy (SBRT) for spinal metastases treated to lesion only (LO) versus the full vertebral body (FVB).
Stereotactic ablative body radiotherapy (SABR) is now considered the standard of care for medically inoperable stage I non-small cell lung cancer (NSCLC). The English National Cancer Registration and Analysis Service (NCRAS) collects data on all patients diagnosed with lung cancer, including information on treatment. We wanted to compare outcomes for patients with stage I NSCLC treated with radical radiotherapy with either SABR or fractionated radiotherapy.
Tumor motion may compromise the accuracy of liver stereotactic radiotherapy. In order to carry out a precise planning, estimating liver tumor motion during radiotherapy has received a lot of attention. Previous approach may have difficult to deal with image data corrupted by noise. The iterative closest point (ICP) algorithm is widely used for estimating the rigid registration of three-dimensional point sets when these data were dense or corrupted. In the light of this, our study estimated the three-dimensi...
The purpose of this study was to evaluate the treatment efficacy of stereotactic body radiotherapy (SBRT) in oligometastatic prostate cancer recurrence and to assess whether there is any relationship between biologically effective dose (BED) and local control (LC).
Shielding protocols such as NCRP 151, IAEA SRS 47 and IPEM 47 are commonly used for the design of radiotherapy facilities. Some work has been accomplished in updating the basic formula with the advent of IMRT but little consideration has been made for unflattened beams and stereotactic techniques apart from for facilities housing devices like the CyberKnife. The inevitable scenario of a stereotactic-only linear accelerator was considered in this study. The necessary shielding requirements were determined ba...
Understanding prostate-specific antigen (PSA) kinetics after radiotherapy plays a large role in the management of prostate cancer (PCa) patients. This is particularly true regarding establishing expectations regarding PSA nadir (nPSA) and PSA bounces, which can be disconcerting. As increasingly more patients are being treated with stereotactic body radiotherapy (SBRT) for low- and intermediate-risk PCa, it is imperative to understand the PSA response to SBRT.
External beam radiotherapy (EBRT) combined with brachytherapy has an essential role in the curative treatment of primary vaginal cancer. EBRT is associated with significant tumour shrinkage, making primary vaginal cancer suitable for image guided adaptive brachytherapy (IGABT). The aim of these recommendations is to introduce an adaptive target volume concept for IGABT of primary vaginal cancer.
The aim of this study was to determine whether a higher biological effective dose (BED) would result in improved local control in patients treated with fractionated stereotactic radiotherapy (FSRT) for their resected brain metastases.
The objective was to evaluate the risk and predictors of developing leptomeningeal disease (LMD) in patients with brain metastases treated with 5-fraction hypofractionated stereotactic radiotherapy (HSRT).
Radiofrequency ablation (RFA) is a standard ablative modality for small liver malignancies. Stereotactic body radiotherapy (SBRT) has emerged although yet suffers a lack of high-level evidence. We performed meta-analyses and a systematic review to integrate the literature and help in clinical decision-making.